Pharmaceutical Companies– tag –
-
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 5 – The Rise of China and Asian ADC Players: How the Global Map Is Being Redrawn and Where Japan Can Stand
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we examin In Part 1 of this series, we explored why the ADC land grab is happening now and how A... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 4 – How to Read ADC Deals: M&A, Licensing, Co-development, and CDMO Agreements
In Part 1 of this series, we looked at why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we exami In Part 1 of this series, we looked at why the ADC land grab is happening now and how ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 3 – Patent Cliffs and ADCs: Why Big Pharma Wants ADCs as Growth Engines for the Next Decade
In Part 1 of this series, we explored why the ADC land grab is happening now and how ADCs fit within the broader landscape of cancer therapies, highli In Part 1 of this series, we explored why the ADC land grab is happening now and how A... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 2 – ADC Structure and Generational Shift: What “Second- and Third-generation” ADCs Really Mean After Enhertu
In Part 1 of this series, we asked why the ADC land grab is happening now, and we positioned ADCs within the broader landscape of cancer therapies, di In Part 1 of this series, we asked why the ADC land grab is happening now, and we posi... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 1 – Why is There an ADC Land Grab Now? Introducing ADC’s Place in Cancer Therapy
Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncology and biopharma news. Over the past few years, headlines about Antibody-Drug Conjugates (ADCs) have become hard to miss in oncolo... -
The Hidden Pitfall of AI Drug Discovery: The Quiet Wall of Reproducibility in Scientific Literature
Introduction: Past Knowledge Is Now the Starting Point of Future Drug Discovery AI-driven drug discovery has become an increasingly central part of modern pharmaceutical R&D. AI-driven drug discovery has become an increasingly centra... -
2026 Global Biotech & Pharma Outlook (Part 2) — Where Technological Progress Is Taking Shape —
Happy New Year. What you will learn AI and Life Sciences Enter a New PhaseThe Evolution of Drug Modalities and Design PhilosophyAdvancing In Vivo Approaches and Control TechnologiesRadiopharmaceuticals and Emerging Therapeutic PlatformsP... -
2026 Global Biotech & Pharma Outlook (Part 1) — Where Science and Innovation Are Heading —
Happy New Year. What you will learn The Current Global Environment for Biotech and PharmaInnovation Continues Beyond Market CyclesEvolving Relationships Between Capital, Policy, and ScienceWhy Global Collaboration Matters More Than EverW... -
Top 10 Global Biotech & Pharma News of 2025 (Ranked #5–#1) — Obesity, ADCs, China Licensing, and M&A Redrew the Map
The second half of 2025’s “top 10” is where the industry’s center of gravity moved. The second half of 2025’s “top 10” is where the industry’s center of gravity moved. The defining themes were clear: obesity drugs entering a second act (... -
Top 10 Global Biotech & Pharma News of 2025 (Ranked #10–#6) — The Year “Policy, Safety, and Supply” Decided Winners
In 2025, innovation alone was not enough. In 2025, innovation alone was not enough. Across biotech and pharma, policy, safety, manufacturing reliability, and reimbursement increasingly determined whether breakthroughs could scale in the ... -
Aging and Cancer Expert Series – Part 10 Future Directions: Where Might Aging × Cancer Research Go in the Next 10–20 Years?
Introduction: A Map of Aging × Cancer Is Starting to Emerge In this final article of the Expert Series, we step back to ask: In this final article of the Expert Series, we step back to ask: What you will learn Introduction: A Map of Agin... -
Aging and Cancer Expert Series – Part 9 Modeling Aging and Cancer: From Cells and Organoids to Mice and Human Cohorts
Introduction: Why “Young” Models Struggle to Capture “Old” Cancer Throughout this Expert Series we have discussed: Throughout this Expert Series we have discussed: What you will learn Introduction: Why “Young” Models Struggle to Capture ... -
Aging and Cancer Expert Series – Part 8 Geriatric Oncology in Practice: Bringing Aging Biology into Cancer Care
Introduction: The Gap Between Aging Biology and Everyday Oncology In earlier parts of this Expert Series, we have explored: In earlier parts of this Expert Series, we have explored: What you will learn Introduction: The Gap Between Aging... -
Aging and Cancer Expert Series – Part 7 Diet, Exercise, Environment, and Geography: External Drivers of Aging × Cancer Risk
Introduction: Adding Lifestyle and Environment to the Genetics–Aging Framework In previous parts of this Expert Series, we focused primarily on “internal” factors: In previous parts of this Expert Series, we focused primarily on “interna... -
Aging and Cancer Expert Series – Part 6 Does Aging Always Promote Cancer? Insights from KRAS-Driven Lung Cancer
Introduction: Questioning the Dogma that “Aging = More Cancer” In previous parts of this Expert Series, we have discussed: In previous parts of this Expert Series, we have discussed: What you will learn Introduction: Questioning the Dogm... -
Aging and Cancer Expert Series – Part 5 Modeling Aging and Cancer: From Cells and Organoids to Whole-Organism and Human Data
Introduction: Why It Is Hard to Model Aging and Cancer Together In earlier parts of this Expert Series, we have discussed: In earlier parts of this Expert Series, we have discussed: What you will learn Introduction: Why It Is Hard to Mod... -
Aging and Cancer Expert Series – Part 4 Reproductive Aging and Women’s Cancers: Linking Ovary, Uterus, and Breast Through Hormones and Molecular Networks
Introduction: Reproductive Aging as a Hub Between Women’s Aging and Cancer In Parts 1–3 of the Expert Series, we discussed: In Parts 1–3 of the Expert Series, we discussed: What you will learn Introduction: Reproductive Aging as a Hub Be... -
Aging and Cancer Expert Series – Part 3 Cancer as a Driver of Systemic Aging: Immune, Tissue, and Treatment-Related Pathways
Introduction: Beyond “Aging → Cancer” to “Cancer → Aging” In the Introductory and earlier Expert Series articles, we mainly focused on the direction: In the Introductory and earlier Expert Series articles, we mainly focused on the direct... -
Aging and Cancer Expert Series – Part 2 Tissue-Specific Aging Profiles and Genetic Background: Why Cancer Prefers Certain Organs
Introduction: Aging Is Not Uniform Across the Body In Part 1 of the Expert Series, we focused on “making aging visible” through epigenetic clocks, single-cell analyses, and image-based metrics. In Part 1 of the Expert Series, we focused ... -
Aging and Cancer Expert Series – Part 1 Making Aging Visible: Epigenetic Clocks, Single-Cell Profiles, and Image-Based Risk Assessment
Introduction: From the Introductory Series to the Expert Series In the Introductory Series (Parts 1–7), we approached the relationship between aging and cancer from multiple angles—historical, molecular, immunologi In the Introductory Se...
